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Abstract: Background: Acute myocardial infarction (AMI) survivors are at risk of major adverse
cardiac events and their risk stratification is a prerequisite to tailored therapeutic approaches.
Biomarkers could be of great utility in this setting. Methods: We sought to evaluate the utility of the
combined assessment of Galectin 3 (Gal-3) and Galectin 3 binding protein (Gal-3bp) for post-AMI
risk stratification in a large, consecutive population of AMI patients. The primary outcomes were:
Recurrent angina/AMI and all-cause mortality at 12 months after the index event. Results: In total, 469
patients were included. The median Gal-3bp was 9.1 µg/mL (IQR 5.8–13.5 µg/mL), while median Gal-3
was 9.8 ng/mL (IQR 7.8–12.8 ng/mL). During the 12 month follow-up, 34 patients died and 41 had
angina pectoris/reinfarction. Gal-3 was associated with all-cause mortality, while Gal-3bp correlated
with the risk of angina/myocardial infarction even when corrected for other significant covariates.
The final multivariable model for mortality prediction included patients’ age, left ventricular ejection
fraction (LVEF), Gal-3, and renal function. The ROC curve estimated for this model has an area
under the curve (AUC) of 0.84 (95%CI 0.78–0.9), which was similar to the area under the ROC curve
obtained using the GRACE score 1-year mortality. Conclusions: The integrated assessment of Gal-3
and Gal-3bp could be helpful in risk stratification after AMI.
Keywords: Galectin 3; Galectin 3 binding protein; myocardial infarction; ischemic cardiomyopathy;
outcome; mortality; reinfarction; angina; recurrent ischemic events
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1. Introduction
Coronary heart disease is still the leading cause of death worldwide [1]. Nevertheless, with the
adoption of coronary revascularization therapy and secondary prevention measures, the survival rates
after acute ischemic events have increased, and, therefore, the prevalence of patients surviving acute
myocardial infarction (AMI) is growing [2]. Patients that experienced an acute ischemic coronary event
are at risk of major adverse cardiac events, such as cardiac death or reinfarction, which is a strong
independent predictor of mortality [3].
Risk stratification of AMI patients is a prerequisite to optimize patient-tailored therapeutic
approaches in order to improve prognosis.
To fulfil this task, biomarkers could be of great utility, since they could provide objective information
that is easily understood. Single biomarkers as well as different combinations of biomarkers have been
proven to be of some utility in defining prognosis in selected patients affected either by ST-elevation
myocardial infarction-STEMI [4] or non ST-elevation myocardial infarction-NSTEMI [5–9].
Data on the usefulness of the integrated use of Galectin 3 and Galectin 3 binding protein in the
setting of acute myocardial infarction are lacking. Galectin 3, a member of the galectin family, is
increased in the left ventricle in the early post-ischemic period [10] that follows AMI and its serum
levels are proven to correlate with the myocardial infarct size (quantified using cardiac magnetic
resonance) [11] and with adverse ventricular remodeling and heart failure [7,12]. Galectin 3 binding
protein (also known as Mac-2 binding protein, M2BP) is a highly glycosylated secreted protein
widely expressed in most normal tissues and body fluids [13]. However, an elevation of galectin-3
binding protein levels was observed in patients with different cancer histotypes, with autoimmune
and infectious diseases, such as hepatitis C, bronchial asthma, or human immunodeficiency virus
infection. Recently, Galectin 3 binding protein levels have been proposed to play an additional
role in cardiovascular disease, specifically, in the development and destabilization of atherosclerotic
plaques [13,14].
In this work, we aimed to determine if Galectin 3 and Galectin 3 binding protein tested together
could be useful for event prediction in a large, unselected consecutive population of patients affected
by myocardial infarction.
2. Material and Methods
2.1. Study Population
We prospectively enrolled 469 consecutive patients, either admitted or transferred to the
Cardiovascular Department of the University Hospital in Trieste with a diagnosis of acute myocardial
infarction (both STEMI and NSTEMI). The diagnosis was established by the cardiologist of the intensive
cardiac care unit, according to ESC guidelines [15,16]. Every patient underwent: a coronary angiography
within the first 24 h after symptoms onset; a detailed clinical exam, including an electrocardiogram
(EKG); a transthoracic echocardiogram; and standard laboratory analyses. Patients were carefully and
continuously monitored for the full length of their hospitalization until they were either discharged
or moved to another department/hospital. Subsequently, patients were subjected to a clinical and
echocardiographic follow-up.
The study protocol was designed according to the ethical guidelines outlined in the Declaration of
Helsinki and was approved by our local ethic committee (N◦ 67/2015). All patients provided written
informed consent. Inclusion criteria were: Age > 18 years, myocardial infarction with clinical onset
in the previous 24 h, and written informed consent for study participation. We excluded patients
with active malignancy with a poor prognosis (life expectancy less than 12 months) and those with an
inability to understand the nature and purpose of the study.
For each enrolled patient, demographic characteristics, past and family history, medical treatment
at admission and discharge, baseline characteristics, clinical data during hospital stay and at discharge,
performed medical procedures, hospital course, and outcome were entered into a database.
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Data on patients’ follow-up were obtained by consulting the electronic health records software,
Cardionet (INSIEL, Trieste, Italy) and G2 Clinical (INSIEL, Trieste, Italy). The data for those who
came from other provinces (Udine, Gorizia, Monfalcone, and Palmanova), were obtained thanks to the
collaboration with the referring hospitals.
The end of the follow-up was either fixed at 12 months after the index event or on the date of
death of the patient, in order to record events that occurred in the first 12 months.
2.2. Definitions, Endpoints, and Follow-Up
The primary outcomes were recurrent angina or myocardial infarction and all-cause mortality at
12 months after the index event.
Angina and myocardial infarction were diagnosed according to ESC guidelines [15,16] and the
third definition of myocardial infarction, respectively [17].
Multistage revascularization (initial revascularization of the culprit lesion only, followed by
revascularization of≥1 lesions as a planned procedure at a later date) was not considered as an end-point.
For the event mortality, our multivariable model was compared to the GRACE score, which was
calculated using the official calculator (www.gracescore.org). The GRACE score for 1 year mortality
was the one used in our analysis.
Multi-vessel critical coronary artery disease was defined as the presence of >70% stenosis in at
least two coronary vessels and detected by coronary angiography.
2.3. Measurements of Biomarkers
Venous blood samples were collected in ethylenediaminetetraacetic (EDTA) tubes within 8 h from
admission, blood samples were then processed in order to obtain plasma (centrifuged at 2500 g for 10’
at 4 ◦C), which was stored at −80 ◦C until analysis was performed.
Plasma levels of Galectin 3 binding protein were measured using the competitive ELISA
immunoassay Human s90K Mac-2 binding protein Paltinum (Life Technologies, Thermofisher, US)
according to the manufacturer’s instructions. Minimum detectable concentration of Galectin 3 binding
protein was 0.012 µg/mL with an intra-assay coefficient of variation (CV) of 5.5%, an inter-assay CV of
11.9%, and a sensitivity of 0.00092 µg/mL.
The plasma concentrations of Galectin 3 were measured using commercially available sandwich
ELISA kit, Galectin 3 (R&D Systems Europe, Abingdon, UK), following the manufacturer’s instructions.
Inter-assay and intra-assay coefficients of variability were 6.2% and 3.7% (Galectin 3), respectively. The
sensitivity of the galectin test was 0.016 ng/mL.
For the determination of plasma levels of IL-1β, a high-sensitivity ELISA kit (Quantikine HS
Human IL-1β Immunoassay, R&D Systems, Inc., Minneapolis, MN, USA) was used. The kit range
was 0.1 to 8 pg/mL. The mean minimum detectable dose was 0.063 pg/mL. IL-1β concentration was
measured by subtracting the 540 nm from the 450 nm spectrophotometer readings.
2.4. Statistical Analysis
Continuous variables are presented as mean values (with the standard deviation) and as median
values (with the interquartile range) when departing from the normality assumption, verified by means
of the Kolmogorov–Smirnov test. Categorical variables are presented as proportions.
Characteristics—measured as continuous variables—of different groups of patients were compared
respectively using ANOVA or Mann–Whitney tests. Categorical variables were compared using the
Chi-square test of the Fisher exact test if necessary.
Linear association between parameters was investigated using the Pearson correlation coefficient
or Spearman Rho, accordingly to the distribution.
The cumulative probability of events during the follow-up was estimated using the Kaplan–Meier
method. The cumulative incidence of angina and reinfarction estimated by the Kaplan–Meier method
was then compared with the cumulative incidence of this event considering death as a competing
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risk, which was estimated using the R library “cmprsk” that implements the method described by
Gray et al. [18]. Cause-specific Cox proportional hazard models were used to assess univariable
predictors of the events of angina and reinfarction, censoring deaths, and standard Cox model for
all-cause mortality. Levels of biomarkers were entered in the Cox analysis as continuous variables
of the original variable or after logarithmic transformation. The multivariable Cox models included
variables significant at the univariable Cox regression and clinically relevant for the specific event.
This model was then reduced by means of a backward conditional stepwise procedure.
Receiver-operating characteristics (ROC) analysis was performed to assess the performance of the
final multivariable model to predict all-cause mortality. Area under the ROC curves of our model was
compared to the area under the ROC of the GRACE score for 1 year mortality using DeLong test.
Classification and regression tree (CRT) analysis, a non-parametric binary recursive partitioning
method, was employed to predict all-cause mortality using the list of variables selected by the
multivariable model [19,20]. This approach had already been used in other studies to improve upon
performance of single biomarkers for distinguishing between different end-points [21]. All the variables
entered in the model were continuous variables and the biomarker level was forced to be the primary
variable in the model. The minimum number of cases was designated as 10 for parent nodes (prior to
split) and 5 for child nodes. In our case, the specific interest was in exploring a “data-driven” cut-off
for the variables of interest in splitting our population.
All statistical tests were two-sided, and statistical significance was set at p < 0.05. Statistical
analyses were performed using the software, IBM SPSS Statistical Package for Mac, version 19, and the
R statistical software, version 3.4.0.
3. Results
3.1. Study Population
The study cohort (Table 1) consisted of 469 consecutive patients with acute myocardial infarction.
In the cohort, 60% of them presented with ST-segment elevation acute myocardial infarction. Mean
age at admission was 67.6 (SD 11.3) years and about 68% were male. A history of previous myocardial
infarction or coronary revascularization (percutaneous coronary intervention or coronary artery bypass
grafting) was present in 19% of patients. Seventy percent of patients were treated with percutaneous
coronary intervention (a drug-eluting stent (DES) was implanted in 73.7% of patients). At pre-discharge
evaluation, the majority of patients was asymptomatic in NYHA class I, with median left ventricular
ejection fraction of 54% (IQR, 47–60%).
The median Galectin 3 binding protein plasma level was 9.1 µg/mL (IQR, 5.8–13.5 µg/mL) and
strongly correlated with critical multivessel coronary artery disease (r = 0.13, p = 0.006), with BMI
(r = 0.18, p < 0.001), as well as with other markers of inflammation: IL-1β (r = 0.1; p = 0.03), hsCRP
(r = 0.24; p < 0.001), and fibrinogen (r = 0.15; p = 0.003). The median value of Galectin 3 was 9.8 ng/mL
(IQR 7.8–12.8 ng/mL). Patients with Galectin 3 higher than the median value were significantly older
and had a significantly higher white blood cell count, when compared with patients with Galectin 3
levels under the median value. Galectin 3 correlated with white blood cell count (r = 0.15, p = 0.002)
and with the markers of inflammation, such as IL-1β (r = 0.16; p = 0.012), hsCRP (r = 0.16; p < 0.001),
and fibrinogen (r = 0.15, p = 0.002). No correlations were observed between Galectin 3 levels and
mononuclear cell counts (r = −0.2, p = 0.67).
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Table 1. Baseline characteristics of all patients.
n = 469
Age 67.63 (11.29)
Male sex (%) 67.8
BMI (kg/m2) 26.82 (4.34)
SBP at admission (mmHg) 136.02 (25.30)
DBP at admission (mmHg) 79.40 (14.47)
Heart rate at admission (bpm) 76.25 (16.82)
Cardiac arrest (%) 3
Left bundle branch block (%) 5.5
Diagnosis (%)
- STEMI
- NSTEMI
60.1
39.9
Killip > 1 (%) 24.4
Hypertension (%) 72.1
Diabetes mellitus (%) 24.7
Smoking (%) 45.2
Dyslipidemia (%) 59.9
Positive family history for IHD (%) 23.9
Known chronic kidney disease (%) 9.2
Peripheral artery disease (%) 7.7
Previous myocardial infarction (%) 18.3
Previous CABG (%) 3.4
Anemia at admission (%) 26.7
Total cholesterol (mg/dL) 189.43 (44.92)
LDL cholesterol (mg/dL) 118.02 (38.44)
HDL cholesterol (mg/dL) 45.26 (12.27)
Triglycerides (mg/dL) 113.5 (82–151)
TnI max (ng/mL) 12.79 (2.86–52.45)
Hb1AC (%) 6 (5.7–6.6)
Hs CRP (mg/dL) 7 (2.8–21.87)
Galectin 3 (ng/mL) 9.8 (7.77–12.77)
Galectin 3 binding protein (g/mL) 9.08 (5.77–13.54)
IL-1 β (pg/mL) 0.59 (0.42–0.97)
Na+ at discharge (mEq/L) 138.94 (3.35)
Hemoglobin at discharge (g/dL) 12.46 (1.67)
MDRD at discharge (mL/min) 69.37 (27.08)
GRACE score at 6 months 120.12 (31.05)
Left atrium area (cm2) 21.46 (5.73)
EDD_I (cm) 3 (4.79)
ESD_I (cm) 1.83 (2.46)
Interventicular septum (cm) 1.32 (1.07)
FS % 34.57 (11.3)
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Table 1. Cont.
n = 469
EDV_I (cm2) 47.04 (38.65–57.2)
ESV_I (cm2) 21.41 (16.05–28.75)
E/A 1.07 (0.77)
E/E’ 11.87 (4.77)
WMSI 1.31 (1.13–1.75)
Left ventricular mass (g) 225.2 (68.26)
Left ventricular ejection fraction % 52 (47–60)
Mitral insufficiency (%)
- Mild
- Moderate
- Severe
63.5
55.4
7.2
1.1
Therapy
- PCI (%)
- CABG
- Medical therapy
70.6
11.1
18.2
Symptom-onset-to-balloon time (h) 2 (1 3.5)
GPIIbIIIa inhibitors (%) 10.2
Multivessel disease >70% (%) 37.5
Severe hemorrhagia (%) 1.1
Ventricular arrhythmias (%) 16.2
Supraventricular arrhythmias (%) 12.6
Brady arrhythmias (%) 7.5
Therapy at discharge (%)
- ACE-I/ARB
- Beta blockers
- Digital
- Amiodarone
- Antialdosteronic agents
- Loop diuretics
- Aspirin
- P2T12 inhibitors
◦ Clopidogrel
◦ Prasugrel
◦ Ticagrelor
- Statins
- Oral antidiabetics
- Insulin
- Warfarin
75.1
77.8
1.1
7.9
11.1
24.1
93.2
40.7
26.7
19.2
89.3
15.4
9.8
8.3
NYHA class at discharge (%)
- NYHA 1
- NYHA 2
- NYHA 3
88.5
8.2
3.2
BMI: body Mass Index; SBP: systolic blood pressure; DBP: diastolic blood pressure; PCI: percutaneous coronary
intervention, CABG: coronary artery bypass graft; MDRD: modification of diet in renal disease; CPR: C-reactive
protein; EDD: end-diastolic diameter; ESD: end-systolic diameter; WMSI: wall motion score index; FS: fractional
shortening; EDV: end-diastolic volume; ESV: end-systolic volume; ARB: angiotensin receptor blockers; NYHA: New
York Heart Association.
J. Clin. Med. 2019, 8, 570 7 of 14
3.2. Outcome During the Follow-Up
During the follow-up period of 12 months, 75 patients reached the primary outcomes: 34 deaths
(7.2%) and 41 angina pectoris requiring hospitalization/revascularization or myocardial infarction
(8.7%). Fourteen patients died within the first month. Thus, they were excluded from the analyses for
the event angina or reinfarction. A summary of the characteristics of the entire population of patients
(n = 469) and of the cohort of patients analyzed for the angina event (n = 455) is provided in Table 1
and in Supplementary Table S1, respectively. The main characteristics of the patients, stratified by
endpoints, are shown in Table 2a,b.
Table 2. (a) Main characteristics of patients stratified by the end-point recurrent angina with need
of rehospitalization/revascularization or myocardial infarction. (b) Main characteristics of patients
stratified by the end-point mortality.
(a)
Final Study Cohort
n = 455
Angina/Reinfarction
n = 41 (9%)
No Angina/Reinfarction
n = 408 (91%) p Value
Diagnosis (%)
- STEMI
- NSTEMI
60
40
36.6
63.4
62.3
37.7 0.002
Treatment:
- PCI
- CABG
- Medical treatment
71.4
11.2
17.4
73.2
4.9
22
64.8
10.8
15.4 0.8
LVEF (%) 54 (47–60) 57 (49–61) 54 (47–60) 0.14
TnI max (ng/mL) 12.5 (2.7–52) 5.78 (1.6–17.2) 13.9 (2.98–65) 0.014
Galectin 3 (ng/mL) 9.8 (7.74–12.3) 10 (8.07–11.5) 9.8(7.73–12.34) 0.8
Galectin 3 binding
protein (µg/mL) 9.07 (5.78–13.44) 9.1 (7.36–14.2) 9.06 (5.75–13.4) 0.55
(b)
Total Population n = 469 Diedn = 35 (7.5%)
Alive
n = 434 (92.5%) p Value
Diagnosis (%)
- STEMI
- NSTEMI
60.1
39.9
57.1
42.9
60.4
39.6 0.72
Treatment (%)
- PTCA
- CABG
- Medical treatment
70.7
11.1
18.2
52.9
14.7
32.4
72.1
10.8
17.1 0.047
LVEF (%) 52 (47–60) 43 (39–55) 55 (48–60) <0.001
TnI max (ng/mL) 12.8 (2.9–52.5) 18.1 (3.6–68.4) 12.3 (2.6–51) 0.36
Galectin 3 (ng/mL) 9.8 (7.77–12.77) 10.49 (10–15.84) 9.74 (7.7–12.2) <0.001
Galectin 3 binding
protein (µg/mL) 9.08 (5.8–13.5) 10.4 (6.3–16.2) 9.03 (5.8–13.4) 0.10
3.2.1. Angina and Reinfarction during Follow-Up
The Kaplan–Meier estimated cumulative rate of angina pectoris requiring
hospitalization/revascularization or reinfarction during the follow-up was 9% and the event
occurred a median of 4.2 (1.5–8.6) months after the index event. When we considered the competing
risk of death, the cumulative incidence of angina or reinfarction during the first 12 months remained
the same at 9% (Figure 1). Among the patients with angina that needed revascularization, only two of
them had a restenosis of the culprit lesion.
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Univariable cause-specific Cox regression analysis revealed that male gender, STEMI diagnosis,
diabetes mellitus, previous acute myocardial infarction, percutaneous coronary intervention or coronary
artery bypass grafting, hemoglobin level at discharge, and Galectin 3 binding protein level were
associated with an increased risk of angina/reinfarction (Supplementary Table S2). Next, we performed
a multivariable analysis including all the significant covariates of the univariable analysis together with
the relevant covariates proposed in a recent study by Arnold et al. [22] (socio-economic variables, such
as medical insurance and level of employment, were excluded since in our country, we have a public
healthcare system). After a backward stepwise variable selection, the following clinical variables were
identified as independent predictors of angina/reinfarction (Table 3a): Male gender, STEMI diagnosis,
and diabetes mellitus. However, with regard to the biomarkers, only plasma Galectin 3 binding protein
levels were significantly associated with the risk of developing another ischemic event during the first
12 months following the acute myocardial infarction (Table 3a).
3.2.2. Mortality during Follow-Up
The Kaplan–Meier estima ed cumulative rate of death was 7.5% and the event occurred a median
of 4.1 (0.4–6.7) months after the index event.
Patients who died during the follow-up had a sig ifica tly higher media value of Galectin 3 at
baseline (p < 0.001) (Table 2b), while the median Galectin 3 binding protein value was not significantly
different in the two groups of patients (Table 2b). In the multivariable Cox regression analysis, after
adjusting for other variables that were significant in the univariable analysis (Supplementary Table S3)
and clinically relevant, LnGalectin 3 levels were significantly associated with the risk of death. The
final multivariable model included patients’ age, left ventricular ejection fraction, LnGalectin 3, and
renal function at discharge, as shown in Table 3b.
Receiver-operating characteristics (ROC) curve was estimated to assess the performance of the
final multivariable model to predict one-year all-cause mortality. The area under the curve (AUC) was
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0.84 (95% CI 0.78–0.90), which was similar to the area under the ROC curve obtained using the GRACE
score 1-year mortality (AUC = 0.82, 95% CI 0.75–0.88), De Long Test, p = 0.16, Figure 2.
In order to verify the “optimal” cut-off of the variables from our final multivariable model to
classify mortality in patients with acute myocardial infarction, a classification and regression tree was
generated. Variables entered in the model were: Galectin 3 after logarithmic transformation, patients’
age, left ventricular ejection fraction, and renal function at discharge. The minimum number of cases
was designated as 10 for parent nodes (prior to split) and 5 for child nodes. The variables which were
maintained in the classification tree were LnGalectin 3, patients’ age, and left ventricular ejection
fraction (which, of note, were the ones with p < 0.05 at the multivariable analysis). The model we
obtained identified the end-point of survival at one year with 100% specificity and 93% of the negative
predictive value (VPN) while its utility in predicting mortality was very low, therefore, it proved to be
a good rule out model for identifying patients with a good outcome at the one-year follow-up. The cut
off of LnGalectin 3 identified by the model was 2.285 on the log scale, which corresponds to the value
9.82 of the original variable, as shown in Supplementary Figure S1.
Table 3. (a) Independent predictors of angina/reinfarction at multivariable Cox proportional hazards
regression analysis. (b) Independent Predictors of mortality at multivariable Cox proportional hazards
regression analysis.
(a)
Predictors
(Ordered by p Value)
Recurrent Angina with Need of
Rehospitalization/Revascularization or Myocardial
Infarction
HR (95% CI) p value
Male gender (vs. female) 4.24 (2.21–8.14) <0.001
STEMI diagnosis (vs. NSTEMI) 3.5 (1.7–7.04) <0.001
Diabetes mellitus (yes vs. no) 2.63 (1.32–5.18) 0.005
Galectin 3 binding protein (for 1 unit increase) 1.04 (1.01–1.08) 0.01
(b)
Predictors
(Ordered by p Value)
All-Cause Mortality
HR (95% CI) p Value
Age
(for 1 y increase) 1.08 (1.04–1.12) <0.001
EF %
(for 10% increase)
(for 5% increase)
0.63 (0.45–0.84)
0.79 (0.68–0.92) 0.001
LnGalectin 3
(for 1 unit increase of original variable)
3.5 (1.54–7.5)
1.12 0.002
MDRD at discharge
(for 10% increase)
(for 5% increase)
0.88 (0.75–1.03)
0.94 (0.86–1.01) 0.09
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Figure 2. ROC curve of our multivariate model compared to the ROC curve of the GRACE score for
mortality at 1 year.
4. Discussion
In this work, we proved for the first time, in a large, unselected, consecutive, real world population
of patients with myoc rdial i farctio , that the dosag of Galectin 3 and Galectin 3 binding protein,
within the first 24 h after the cute eve t, could help to better stratify patients’ risk and to provide
additional and integrated information ab ut the probability of distinct eve ts. Specifically, Galectin
3 was an independent predictor of all-cause mort lity, while Galectin 3 binding protein levels wer
independently ass ciated with a higher risk of angina pectoris or reinfarction. Importantly, the
characteristics of the population enrolled in our study are in accordance with what merges from
international [2,2 ,24] and national e idemiological studies [25]. Also, the rates of both one year
mortality and one y ar angina/reinfarction observed in our cohort of patients are in line it those
reported by the literature [22,26].
This association with distinct events may relate to the fact t at each biomarker reflects different
pathobiologic l axes of the post myocardial infarction response [4,5].
Specifically, Galectin 3 binding protein is a highly glycosylated protein, expressed in most normal
tissue and body fluids [13], that seems to be involved in different physiological processes, such as
cell adhesion and immunomodulation [13,14]. Even if data on the pathophysiological role played
by Galectin 3 binding protein in cardiovascular disease are still lacking, it has been suggested that
its levels correlate with a poor cardiovascular outcome [13]. Concerning our population study, we
observed that the levels of Galectin 3 binding protein detected in our population were higher than
those detected in both healthy individuals [8,27], and in patients with stable coronary disease [14]. This
finding is in line with the knowledge that if Galectin 3 binding protein has a role in the inflammatory
process which leads to progression and destabilization of atherosclerotic plaques [13], it should be
highly expressed in patients who suffered acute myocardial infarction, which in most cases is due to a
thrombotic occlusion of a coronary artery, following a plaque rupture [28]. We also found a positive
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correlation between Galectin 3 binding protein values and other markers of inflammation, such as
IL-1β, hsCRP, and fibrinogen. This finding is in line with the critical role played by inflammation in
atherothrombosis, which can increase the risk of cardiovascular events, independently from cholesterol
levels [29,30].
Further, in our study, patients with multi-vessel critic coronary artery disease (defined as the
presence of >70% stenosis in at least two coronary vessels and detected by coronary angiography) had
a higher median value of Galectin 3 binding protein than those with less critic coronary artery disease.
Also, Xie et al. recently demonstrated that Galectin 3 binding protein levels positively correlate with
the presence and extent of complex lesions [13].
Reinfarction after an acute myocardial infarction is a strong independent predictor of mortality [3].
Galectin 3 binding protein turned out to be able to predict the risk of angina/reinfarction at the 1
year follow-up in patients who were alive 30 days after the index acute myocardial infarction. This
correlation remained significant even when adjusted for clinical variables, which had proven to be
predictors of angina/reinfarction in a recent study by Arnold et al. [22]. The association between levels
of Galectin 3 binding protein and a higher risk of developing another ischemic event in the first year
following acute myocardial infarction is supported by the role of Galectin 3 binding protein in the
inflammatory process, which leads to progression and destabilization of atherosclerotic plaques [13].
Our finding is consistent with the CANTOS trial, which showed that anti-inflammatory therapy with
the anti-IL1β antibody, Canakinumab, was able to lower the recurrence of cardiovascular events,
independently of lipid-lowering therapy [30]. As opposed to what was proven by Sugiura et al. [8], no
association was found between Galectin 3 binding protein levels and mortality. This discrepancy can
be due to the fact that our population was larger, and that we considered mortality for any cause rather
than cardiovascular mortality only.
Galectin 3, a member of the galectin family that can be found both in many normal tissues and
in different tumors, is involved in different physiological and pathophysiological conditions, such as
development, immunity, neoplastic transformation, and metastatic spread [31]. Importantly, Galectin
3 has emerged as an independent predictor of all-cause mortality, cardiovascular death, and the
occurrence of heart failure following acute coronary syndromes [7]. The Galectin 3 values of our
patients are in line with values reported in other studies conducted on patients with cardiovascular
disease [32] and are higher than those detected in healthy individuals [27]. Patients with Galectin 3
levels higher than the median value were significantly older and had significantly higher white blood
cell counts, when compared with patients with Galectin 3 levels under the median value, as observed
by Tsai et al. [32]. Galectin 3 was an independent predictor of all-cause mortality, while it was not
able to predict the development of angina pectoris or myocardial infarction. The correlation between
Galectin 3 levels and a higher risk of one-year all-cause death remained statistically significant, even
when corrected with clinical variables associated with a higher mortality risk. This finding can be
explained by the fact that, while in the first period following acute myocardial infarction Galectin 3
seems to be part of a survival mechanism to cope with the ischemic insult [10], actively contributing
to the reparative processes in the infarcted area [12], in later time points, it supports the transition
from acute to chronic inflammation and fibrosis. These latter two are pivotal mechanisms for the
development of adverse ventricular remodeling [7,12]. Since the development of adverse ventricular
remodeling after myocardial infarction is a strong predictor of mortality and heart failure [33], the
association between Galectin 3 levels and left ventricular remodeling after myocardial infarction,
previously proven by di Tano et al. [34], can be the basis of the higher risk of mortality observed in
patients with higher levels of Galectin 3 in our study.
In the multivariable analysis, we found that Galectin 3 levels, renal function at discharge, patients’
age, and left ventricular ejection fraction were associated with 1 year mortality. These four parameters
are objective and can be easily obtained. Of note, our multivariable model has proven to be comparable
to the GRACE score [35] in predicting one year mortality. The GRACE score is validated in multiple
databases and it includes more variables [35]. Further, we identified a Galectin 3 value of 9.82 ng/mL
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as discriminating between lower or increased mortality, and this value is in line with that previously
identified by Tsai et al. [32]. The identification of a cut off value could be of great utility in patients’
risk stratification.
The pathophysiological role of the tested biomarkers in the development of the different outcomes
that they predict may open the road to the development of new targeted therapies. Indeed, it has
been proven that mineralocorticoid receptor antagonists are able to down-regulate the expression
of Galectin 3 in the infarcted myocardium of animal models and this down-regulation of Galectin
3 correlates with lower expression levels of fibrosis and inflammatory markers [36]. An interaction
between the concentration of Galectin 3 and treatment with beta blockers and antialdosteronic drugs
has also been observed in humans [37] so it can be hypothesized that serial measures of Gal-3 could be
helpful to decide the most appropriate therapeutic schemes for each patient.
Possible limitations of our study are that we tested biomarker levels only once, within 24 h
following myocardial infarction, while it would be of great interest to see if changes in biomarker levels
over time could correlate with patients’ prognosis. We were not able to discriminate between cardiac
and non-cardiac death. However, since patients with a short life expectancy were considered ineligible
to be enrolled in our study, we can suppose that cardiac death is very likely in our population. Finally,
we did not focus on left ventricular remodeling in this work, but we are now collecting follow-up
echocardiographic data in order to investigate if there is any relationship between Galectin 3 levels
and adverse remodeling of the left ventricle as suggested by Di Tano et al. [34].
5. Conclusions
In conclusion, in the present study, we showed that by measuring Galectin 3 and Galectin 3
binding protein in the first hours after myocardial infarction, we can better assess patients’ risk.
Galectin 3 turned out to provide information about all-cause mortality, while Galectin 3 binding
protein proved to be of better utility in predicting the risk or recurrent angina with the need of
revascularization/hospitalization or myocardial infarction.
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